Modified-release (MR) drug products are designed to provide controlled drug delivery over time, offering therapeutic and compliance advantages.
Oral Pro‑Transferosome Tablets of Carica papaya Leaf Extract: Box–Behnken Optimization and In Silico Mechanistic Insights for Dengue‑Associated Thrombocytopenia
Carica papaya L. leaf extract has long been recognized for its therapeutic potential in dengue-associated thrombocytopenia through enhancement of platelet production and inhibition of dengue viral proteases.
Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development
Driving Growth with Integrated Software, Services, and AI-Enabled Ecosystem
Comprehensive PBPK Evaluation of Phenytoin and Indomethacin: Dose, Age, Pregnancy and Drug–Drug Interaction Insights
Understanding the pharmacokinetics (PK) of antiepileptic and anti-inflammatory drugs under different physiological conditions is essential for optimizing therapy.
Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date
Conference call to be on Thursday, January 8, 2026, at 5 p.m. ET
Descriptor-First Approach for ADMET Prediction in the PolarisHub Antiviral Challenge
The prediction of absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties remains a central bottleneck in small-molecule discovery.
Vision, Mission and Values
To improve health through innovative solutions.
Mechanistic Modeling of Intramuscular Administration of a Long-acting Injectable Accounting for Tissue Response At the Depot Site
The tissue response to long-acting injectables (LAIs) suspension injection may impact the product in vivo performance.
Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions
Validated engines and AI-orchestrated ecosystem align with the emerging regulatory framework
Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous Data
Model-based meta-analysis (MBMA) informs key drug development decisions by integrating data, published or unpublished, from multiple studies.
Physiologically Based Pharmacokinetic Simulations Using Transdermal Compartmental Absorption and Transit Model (TCAT) for RLS-1496 Dermal Preparations
RLS-1496 is a senolytic drug formulated as a cream for topical administration and currently in Phase 1 clinical trials for dermatological conditions. A 1% cream strength was determined to be a safe starting dose for first-in-human studies, based onnonclinical toxicology studies.
Development of an Improved Dissolution Testing Method as an Alternative to Animal Testing
This study aimed to evaluate the potential of an improved flow-through cell dissolution method as an alternative to animal testing for predicting the in vivo behavior of immediate-release formulations.
Integrating PBPK Modeling and Developability Assessment to Guide Early Phase Formulation Strategy
Physiologically based pharmacokinetic (PBPK) modeling is a core element of the early drug and formulation development workflow, enabling data-driven decisions that accelerate timelines and de-risk programs.
Derisking Formulation Strategies Using PBBM: Mechanistic Case Studies on Evaluating Food Effects and Guiding Dissolution Specifications
Understand how PBBM mechanistically integrates formulation dependent processes—such as dissolution, precipitation, gastrointestinal transit, and metabolism—to simulate oral drug absorption under varying prandial conditions.
GastroPlus® X.2: The Deep Dive Webinar Series – How New AI-Powered Tools Can Support Your PBPK Modeling
What if you could design a complex workflow, then set it into motion with a single click?
Use of PBBM-PBPK To Predict Mesalamine Delayed-Release Oral Drug Products Performance in Both Healthy and Disease Physiologies
Mesalamine (5-aminosalicylic acid (5-ASA)) is an anti-inflammatory drug indicated for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD).
From In Vitro Dissolution Testing to In Vivo Clinical Pharmacokinetic Prediction Using PBPK Models for Oral Cavity Drug Products
This work develops a novel in vitro to in vivo extrapolation (IVIVE) method for the prediction of in vivo pharmacokinetic (PK) for oral cavity drug products (DP).
PBPK-Based Prediction of Obesity-Mediated Changes in Small Molecule Pharmacokinetics
Obesity is associated with fat accumulation, combined with physiological alterations, (changes in organ sizes, blood flows, and metabolic enzyme activities).
Predicting Aflibercept Local Exposure in Humans Using an Ocular PBPK Model
Developing both innovative and generic ophthalmic drug products remains a significant hurdle for the pharmaceutical industry.